Thus, it offers a possibility of safe testing possible synergistic effects of DC-CIK cell therapy with Wnt/beta-catenin inhibitors and, even more broadly, with immune checkpoint inhibitors applicable for GBM treatment. This evidence concerns the gene CTNNB1 and glioblastoma.